ALL Therapeutics

Global socioeconomic disparities in ALL: treatment challenges

Marisa Felice (Argentina) and Shaun Fleming (Australia) discussed socioeconomic disparities in the treatment of pediatric and adult...

Real-world efficacy of CAR T cells for posttransplant relapse in patients with B-ALL

In this article, we summarize the results of the first real-world study of tisa-cel in patients with B-ALL.

Dasatinib with intensive chemotherapy in newly diagnosed pediatric patients with Ph+ ALL

This article summarizes a publication by Hunger et al. on the efficacy of dasatinib with intensive chemotherapy...

Ponatinib vs imatinib as a frontline treatment for patients with Ph+ ALL

This article summarizes a publication by Ribera et al. comparing the efficacy of ponatinib vs imatinib as a frontline treatment...

ECOG-ACRIN E1910 subgroup analysis: Impact of age and MRD on blinatumomab outcomes in newly diagnosed Ph− B-ALL

Here, we summarize the subgroup analysis of the ECOG-ACRIN E1910 study evaluating the...

Results from the phase III AALL1331 trial: Blinatumomab in low-risk children and AYA patients with B-ALL in first relapse

Here, we summarize an article by Hogan et al. on the efficacy and safety...

Is mini-hyper-CVD plus venetoclax safe and effective in patients with R/R Ph- ALL?

During the 2023 European Hematology Association (EHA) Congress, the ALL Hub spoke to Fadi Haddad, MD Anderson Cancer...

Novel treatment in Philadelphia negative ALL: Key updates from EHA 2023

Here, we summarize three presentations discussing novel treatments for adult patients with Philadelphia chromosome-negative ALL,...